journal article·2025-11Open access

PSMD14‐Mediated LDHA Deubiquitination Upregulates ACLY Expression via H3K18 Lactylation to Promote Lipid Synthesis and Pancreatic Cancer Progression

Ri‐Shang Lu, Li‐Kun Ren, Xiao‐Bin Fei, Song‐Bai Liu, Yong‐Jia Gao, Jun‐Yi Hou, Chi Wang, Peng Liu, Chang‐Hao Zhu, Xing Wang, Yao‐Zhen Pan

Advanced Science· Volume 12· Issue 44

Abstract

Abstract Aberrant lipid metabolism is intimately linked to tumor progression. As a pivotal post‐translational modification, ubiquitination regulates diverse oncogenic processes. However, the interplay between ubiquitination and lipid metabolic dysregulation in pancreatic cancer (PC), along with its underlying molecular mechanisms, remains poorly understood. Here, it is demonstrated that glycolytic enzyme lactate dehydrogenase A (LDHA) potentiates lipid biosynthesis under the regulation of deubiquitinases. Specifically, PSMD14 directly binds and stabilizes LDHA through its deubiquitinase activity, resulting in intracellular lactate accumulation. Elevated lactate levels enhance histone lactylation marks, which transcriptionally activate ATP citrate lyase (ACLY) to promote malignant progression via fatty acid synthesis pathway activation. This study reveals a previously unrecognized role of PSMD14‐derived lactate in mediating histone lactylation‐coupled lipid deposition and tumor progression. Therapeutic co‐targeting of PSMD14 and glycolytic lactylation significantly suppresses tumor growth in patient‐derived xenograft models, suggesting a promising combinatorial strategy for pancreatic cancer treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer, Hypoxia, and Metabolism · Ubiquitin and proteasome pathways · Cancer, Lipids, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Clinical Medicine Guizhou Medical University Guiyang 550004 China

Department of Hepatobiliary Surgery Zhejiang Provincial People's Hospital Hangzhou Medical University Hangzhou 310014 China

Department of Hepatobiliary Surgery Baiyun Hospital Guizhou Medical University Guiyang 550001 China

Department of Hepatobiliary Surgery Affiliated Hospital of Guizhou Medical University Guiyang 550001 China

Department of Hepatobiliary Surgery Affiliated Cancer Hospital of Guizhou Medical University Guizhou Medical University Guiyang 550001 China

Funding

National Natural Science Foundation of China · Science and Technology Program of Guizhou Province

References (62)

Show source-provided references
1. 10.3322/caac.2187110.3322/caac.21871 ↗
2. 10.1016/j.cell.2023.02.01410.1016/j.cell.2023.02.014 ↗
3. 10.1053/j.gastro.2023.02.01210.1053/j.gastro.2023.02.012 ↗
4. 10.1146/annurev-pathmechdis-031621-02460010.1146/annurev-pathmechdis-031621-024600 ↗
5. 10.1186/s13045-024-01613-x10.1186/s13045-024-01613-x ↗
6. 10.1038/s41575-023-00856-210.1038/s41575-023-00856-2 ↗
7. 10.1136/gutjnl-2021-32607010.1136/gutjnl-2021-326070 ↗
8. 10.1186/s13045-022-01348-710.1186/s13045-022-01348-7 ↗
9. 10.1038/s43018-023-00647-310.1038/s43018-023-00647-3 ↗
10. 10.1002/cac2.1236010.1002/cac2.12360 ↗
11. 10.1158/0008-5472.CAN-22-267910.1158/0008-5472.CAN-22-2679 ↗
12. 10.1002/anie.20210722310.1002/anie.202107223 ↗
13. 10.1084/jem.2020160610.1084/jem.20201606 ↗
14. 10.1016/j.semcancer.2024.12.00210.1016/j.semcancer.2024.12.002 ↗
15. 10.1016/j.cmet.2022.09.02310.1016/j.cmet.2022.09.023 ↗
16. 10.1038/s43018-023-00702-z10.1038/s43018-023-00702-z ↗
17. Liang X. H. · Acta Pharmacol. Sin. · 2011 · 2024 · 45
18. 10.1016/j.trecan.2020.10.00410.1016/j.trecan.2020.10.004 ↗
19. 10.3390/cells1105085110.3390/cells11050851 ↗
20. 10.1016/j.tcb.2023.09.00110.1016/j.tcb.2023.09.001 ↗
21. 10.1186/s12943-024-02046-310.1186/s12943-024-02046-3 ↗
22. 10.1002/advs.20230380710.1002/advs.202303807 ↗
23. 10.1038/s41568-023-00633-y10.1038/s41568-023-00633-y ↗
24. 10.1038/s41419-023-05706-210.1038/s41419-023-05706-2 ↗
25. 10.1038/s41467-022-29846-910.1038/s41467-022-29846-9 ↗
26. 10.1126/science.107589810.1126/science.1075898 ↗
27. 10.1016/j.cellsig.2022.11049010.1016/j.cellsig.2022.110490 ↗
28. 10.1038/emboj.2012.23210.1038/emboj.2012.232 ↗
29. 10.1016/j.neo.2018.02.00510.1016/j.neo.2018.02.005 ↗
30. 10.1002/pros.2383810.1002/pros.23838 ↗
31. 10.1016/j.ebiom.2019.10.03910.1016/j.ebiom.2019.10.039 ↗
32. 10.1016/j.canlet.2023.21644410.1016/j.canlet.2023.216444 ↗
33. 10.1016/j.semcancer.2022.11.00710.1016/j.semcancer.2022.11.007 ↗
34. 10.1007/s13238-021-00846-710.1007/s13238-021-00846-7 ↗
35. 10.1111/cpr.1347810.1111/cpr.13478 ↗
36. 10.1080/15548627.2023.224976210.1080/15548627.2023.2249762 ↗
37. 10.1158/0008-5472.CAN-23-351310.1158/0008-5472.CAN-23-3513 ↗
38. 10.1017/erm.2022.4210.1017/erm.2022.42 ↗
39. 10.1186/s13059-022-02775-y10.1186/s13059-022-02775-y ↗
40. 10.1038/s41419-024-06930-010.1038/s41419-024-06930-0 ↗
41. 10.3724/abbs.202304510.3724/abbs.2023045 ↗
42. 10.1016/j.cell.2024.10.04710.1016/j.cell.2024.10.047 ↗
43. 10.1038/s41423-021-00781-x10.1038/s41423-021-00781-x ↗
44. Jiang T. · Mol. Cancer · 2024 · 23 · 881
45. 10.1038/s41576-022-00562-w10.1038/s41576-022-00562-w ↗
46. 10.3389/fphar.2024.138320310.3389/fphar.2024.1383203 ↗
47. 10.3389/fphys.2022.85519310.3389/fphys.2022.855193 ↗
48. 10.1038/s41420-022-01241-910.1038/s41420-022-01241-9 ↗
49. 10.1038/s41467-022-29846-910.1038/s41467-022-29846-9 ↗
50. 10.7150/ijbs.11129010.7150/ijbs.111290 ↗
51. 10.7150/thno.4610910.7150/thno.46109 ↗
52. 10.1002/1878-0261.1307610.1002/1878-0261.13076 ↗
53. 10.1016/j.tem.2022.07.00410.1016/j.tem.2022.07.004 ↗
54. 10.1038/nature2405710.1038/nature24057 ↗
55. 10.1038/s41586-019-1678-110.1038/s41586-019-1678-1 ↗
56. 10.1186/s12943-024-02008-910.1186/s12943-024-02008-9 ↗
57. 10.1016/j.canlet.2019.12.01010.1016/j.canlet.2019.12.010 ↗
58. 10.1016/j.molmed.2023.05.00610.1016/j.molmed.2023.05.006 ↗
59. 10.1038/s41571-023-00736-310.1038/s41571-023-00736-3 ↗
60. 10.1056/NEJMoa240071210.1056/NEJMoa2400712 ↗
61. 10.7150/thno.4610910.7150/thno.46109 ↗
62. 10.1038/s41388-024-03092-310.1038/s41388-024-03092-3 ↗